期刊
NATURE MEDICINE
卷 28, 期 5, 页码 1083-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01734-1
关键词
-
资金
- Defense Advanced Research Projects Agency [D18AC00006]
- Flu laboratory
- Centers for Disease Control and Prevention (CDC) COVID-19 baseline genomic surveillance contract sequencing [75D30121C10501]
- CDC Broad Agency Announcement [75D30120C09605]
- National Institute of Allergy and Infectious Diseases [U19AI110818, U01AI151812]
- National Science Foundation Graduate Research Fellowship [1745302]
- National Institute of General Medical Sciences [T32GM007753]
- Howard Hughes Medical Institute
- Princeton University
A microfluidic CRISPR-based platform called mCARMEN enables multiplexed and high-throughput identification of a wide range of respiratory viruses, including specific SARS-CoV-2 variants. The platform combines cost-effectiveness, diagnostic-grade performance, and a streamlined workflow for clinical use.
A microfluidic CRISPR-based platform enables multiplexed and high-throughput identification of a wide range of respiratory viruses, including the ability to identify specific SARS-CoV-2 variants such as Delta and Omicron. The coronavirus disease 2019 (COVID-19) pandemic has demonstrated a clear need for high-throughput, multiplexed and sensitive assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses and their emerging variants. Here, we present a cost-effective virus and variant detection platform, called microfluidic Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (mCARMEN), which combines CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical use. We developed the mCARMEN respiratory virus panel to test for up to 21 viruses, including SARS-CoV-2, other coronaviruses and both influenza strains, and demonstrated its diagnostic-grade performance on 525 patient specimens in an academic setting and 166 specimens in a clinical setting. We further developed an mCARMEN panel to enable the identification of 6 SARS-CoV-2 variant lineages, including Delta and Omicron, and evaluated it on 2,088 patient specimens with near-perfect concordance to sequencing-based variant classification. Lastly, we implemented a combined Cas13 and Cas12 approach that enables quantitative measurement of SARS-CoV-2 and influenza A viral copies in samples. The mCARMEN platform enables high-throughput surveillance of multiple viruses and variants simultaneously, enabling rapid detection of SARS-CoV-2 variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据